HCA Healthcare, Inc.’s Stock Price Takes a Dip to $317.18, Recording a 2.90% Decrease

HCA Healthcare, Inc. (HCA)

317.18 USD -9.47 (-2.90%) Volume: 1.23M

HCA Healthcare, Inc.’s stock price stands at 317.18 USD, experiencing a dip of -2.90% in the current trading session, with a trading volume of 1.23M. Despite today’s decline, HCA’s stock maintains a strong performance with a Year-to-Date (YTD) increase of +17.18%, reflecting its robust market presence and investor confidence.

Latest developments on HCA Healthcare, Inc.

In a series of key events leading up to today’s HCA Healthcare stock price movements, several executives sold substantial amounts of company stock, with one executive selling over $500k and an EVP offloading over $1.9 million. Meanwhile, Fisher Asset Management LLC has shown confidence by buying new shares in HCA Healthcare, Inc. (NYSE:HCA). However, Zacks Research analysts have lowered earnings estimates for the healthcare firm. In a positive development, HCA Florida Healthcare has broken ground on a new hospital in Yulee.

A look at HCA Healthcare, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, HCA Healthcare has a positive long-term outlook. With high scores in Growth and Momentum, the company is positioned well for future expansion and market performance. This indicates that HCA Healthcare is expected to experience strong growth and maintain its momentum in the healthcare sector.

While the company has lower scores in Value and Dividend, it still has a solid Resilience score, suggesting that HCA Healthcare is well-equipped to weather any potential challenges or economic downturns. Overall, HCA Healthcare’s strong performance in Growth and Momentum bodes well for its future prospects in providing healthcare services to patients in the United States.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma